Yaël P. Mossé

13.0k citations

96 papers · 4.6k indexed · 1 hit paper · h-index 35

Neurology top 0.2%
- Neuroblastoma Research and Treatments 83
Cancer Research top 1%
- Cancer, Hypoxia, and Metabolism 35
- Cancer Genomics and Diagnostics 6
Oncology top 2%
- Lung Cancer Research Studies 20
Molecular Biology top 5%
- Cancer therapeutics and mechanisms 30
Genetics top 5%
- Virus-based gene therapy research 4
Epidemiology
- Neuroendocrine Tumor Research Advances 9
Cell Biology
- Microtubule and mitosis dynamics 6

Co-authors: John M. Maris Edward F. Attiyeh Kristina A. Cole Sharon J. Diskin Brenda J. Weigel Susan M. Blaney Andrew Wood Garrett M. Brodeur
Cited by: Neurology Cancer Research Oncology
Journals: New England Journal of Medicine (1 paper)Proceedings of the National Academy of Sciences (2 papers)Journal of Clinical Oncology (22 papers)
Partner nations: United States Canada United Kingdom

In The Last Decade

Yaël P. Mossé

93 papers receiving 4.6k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Yaël P. Mossé

Since Specialization

Citations

This map shows the geographic impact of Yaël P. Mossé's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yaël P. Mossé with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yaël P. Mossé more than expected).

Fields of papers citing papers by Yaël P. Mossé

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yaël P. Mossé. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yaël P. Mossé. The network helps show where Yaël P. Mossé may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Yaël P. Mossé, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Yaël P. Mossé Line = papers co-authored together Yaël P. Mossé links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High-Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study Journal of Clinical Oncology ·Esther R. Berko,Arlene Naranjo,Alexander A. Daniels,Samantha N. McNulty,Kateryna Krytska,Todd E. Druley,Kristin Zelley,Balakrishna Koneru,Lulu Chen,Grace Polkosnik,Meredith S. Irwin,Rochelle Bagatell,John M. Maris,C. Patrick Reynolds,Steven G. DuBois,Julie R. Park,Yaël P. Mossé	2025	1
2	Lineage dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and -independent immunotherapeutic targets Neuro-Oncology ·Nathan M. Kendsersky,Michal Odrobina,Nathaniel W. Mabe,Alvin Farrel,Liron D. Grossmann,Matthew Tsang,David Groff,Adam J. Wolpaw,Alaa Narch,Francesca Zammarchi,Patrick H. van Berkel,Chi V. Dang,Yaël P. Mossé,Kimberly Stegmaier,John M. Maris	2025	1
3	Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma Molecular Cancer Therapeutics ·Smita Matkar,Michael P. East,Timothy J. Stuhlmiller,Gabriela M. Witek,Alvin Farrel,Steven Pastor,Denis O. Okumu,Anne Kennedy,Joshua R. Kalna,Esther R. Berko,Colleen E. Casey,Kateryna Krytska,Khushbu Patel,Jo Lynne Rokita,Mark Gerelus,John M. Maris,Gary L. Johnson,Yaël P. Mossé	2025	2
4	Evaluation of the DLL3-targeting Antibody–Drug Conjugate Rovalpituzumab Tesirine in Preclinical Models of Neuroblastoma Cancer Research Communications ·Kateryna Krytska,Colleen E. Casey,Jennifer Pogoriler,Daniel Martínez,Komal S. Rathi,Alvin Farrel,Esther R. Berko,Matthew Tsang,Renata R. Sano,Nathan M. Kendsersky,Stephen W. Erickson,Beverly A. Teicher,Kumiko Isse,Laura R. Saunders,Malcolm A. Smith,John M. Maris,Yaël P. Mossé	2022	5
5	Venetoclax-based Rational Combinations are Effective in Models of MYCN -amplified Neuroblastoma Molecular Cancer Therapeutics ·Krista M. Dalton,Kateryna Krytska,Timothy L. Lochmann,Renata Sano,Colleen E. Casey,Alessia D'Aulerio,Qasim A. Khan,Giovanna Stein Crowther,Colin M. Coon,Jinyang Cai,Sheeba Jacob,Richard Kurupi,Bin Hu,Mikhail G. Dozmorov,Patricia Greninger,Andrew J. Souers,Cyril H. Benes,Yaël P. Mossé,Anthony C. Faber	2021	13
6	Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912) Clinical Cancer Research ·Jennifer H. Foster,Stephan D. Voss,David Hall,Charles G. Minard,Frank M. Balis,Keith D. Wilner,Stacey L. Berg,Elizabeth Fox,Peter C. Adamson,Susan M. Blaney,Brenda J. Weigel,Yaël P. Mossé	2021	61
7	A safety and feasibility trial of ¹³¹I‐MIBG in newly diagnosed high‐risk neuroblastoma: A Children's Oncology Group study Pediatric Blood & Cancer ·Brian Weiss,Gregory A. Yanik,Arlene Naranjo,Fan F. Zhang,Wendy Fitzgerald,Barry L. Shulkin,Marguerite T. Parisi,Heidi V. Russell,Stephan A. Grupp,Luke Pater,Peter Mattei,Yaël P. Mossé,Hollie Lai,Jason A. Jarzembowski,Hiroyuki Shimada,Judith G. Villablanca,Roger Giller,Rochelle Bagatell,Julie R. Park,Katherine K. Matthay	2021	23
8	Advances and Challenges in Pediatric and Childhood Cancers Cancer Cell ·Cynthia Hawkins,Stefan M. Pfister,David Jones,Nirali N. Shah,Richard J. Gilbertson,E. Alejandro Sweet‐Cordero,Michael A. Dyer,Yaël P. Mossé,Michelle Haber,Steven G. DuBois	2020	2
9	Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children’s Oncology Group phase 1 consortium study (ADVL1212) Cancer Chemotherapy and Pharmacology ·Emily Greengard,Yaël P. Mossé,Xiaowei Liu,Charles G. Minard,Joel M. Reid,Stephan D. Voss,Keith D. Wilner,Elizabeth Fox,Frank M. Balis,Susan M. Blaney,Peter C. Adamson,Brenda J. Weigel	2020	18
10	A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921) Clinical Cancer Research ·Yaël P. Mossé,Elizabeth Fox,David T. Teachey,Joel M. Reid,Stephanie L. Safgren,Hernán Carol,Richard B. Lock,Peter J. Houghton,Malcolm A. Smith,David Hall,Donald A. Barkauskas,Mark Krailo,Stephan D. Voss,Stacey L. Berg,Susan M. Blaney,Brenda J. Weigel	2019	79
11	Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group Study Journal of Clinical Oncology ·Yaël P. Mossé,Stephan D. Voss,Megan S. Lim,Delphine Rolland,Charles G. Minard,Elizabeth Fox,Peter C. Adamson,Keith D. Wilner,Susan M. Blaney,Brenda J. Weigel	2017	247
12	Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma Clinical Cancer Research ·Andrew Wood,Kateryna Krytska,Hannah T. Ryles,Nicole R. Infarinato,Renata Sano,Theodore D. Hansel,Lori S. Hart,Frederick J. King,Timothy R. Smith,Edward Ainscow,Kathryn B. Grandinetti,Tove Tuntland,Sunkyu Kim,Giordano Caponigro,You He,Shiva Krupa,Nanxin Li,Jennifer L. Harris,Yaël P. Mossé	2016	67
13	The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma Cancer Discovery ·Nicole R. Infarinato,Jin H. Park,Kateryna Krytska,Hannah T. Ryles,Renata Sano,Katherine M. Szigety,Yimei Li,Helen Y. Zou,Nathan V. Lee,Tod Smeal,Mark A. Lemmon,Yaël P. Mossé	2015	116
14	Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma Clinical Cancer Research ·Kateryna Krytska,Hannah T. Ryles,Renata Sano,Pichai Raman,Nicole R. Infarinato,Theodore D. Hansel,Monish Ram Makena,Michael M. Song,C. Patrick Reynolds,Yaël P. Mossé	2015	76
15	Phase I/II study of 131I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma British Journal of Cancer ·Steven G. DuBois,Steven L. Allen,Melissa A. Bent,Joan F. Hilton,Fabienne Hollinger,R A Hawkins,Jesse Courtier,Yaël P. Mossé,Katherine K. Matthay	2015	44
16	Genomic copy number determination in cancer cells from single nucleotide polymorphism microarrays based on quantitative genotyping corrected for aneuploidy Genome Research ·Edward F. Attiyeh,Sharon J. Diskin,Marc A. Attiyeh,Yaël P. Mossé,Cuiping Hou,Eric M. Jackson,Cecilia Kim,Joseph Glessner,Håkon Håkonarson,Jaclyn A. Biegel,John M. Maris	2009	66
17	A Functional Screen Identifies miR-34a as a Candidate Neuroblastoma Tumor Suppressor Gene Molecular Cancer Research ·Kristina A. Cole,Edward F. Attiyeh,Yaël P. Mossé,Michael P. LaQuaglia,Sharon J. Diskin,Garrett M. Brodeur,John M. Maris	2008	242
18	Cortical Processing of Respiratory Occlusion Stimuli in Children with Central Hypoventilation Syndrome American Journal of Respiratory and Critical Care Medicine ·Jingtao Huang,Carole L. Marcus,Preetam Bandla,Michael S. Schwartz,Michelle Pepe,John Samuel,Howard B. Panitch,Ruth Bradford,Yaël P. Mossé,John M. Maris,Ian M. Colrain	2008	12
19	The microRNA miR-34a is a candidate 1p36 tumor suppressor gene in neuroblastoma Cancer Research ·Kristina A. Cole,Edward F. Attiyeh,Yaël P. Mossé,Sharon J. Diskin,Garrett M. Brodeur,John M. Maris	2007	1
20	Measurement and relevance of neuroblastoma DNA copy number changes in the post-genome era Cancer Letters ·Yaël P. Mossé,Joel Greshock,Barbara L. Weber,John M. Maris	2005	13

About Yaël P. Mossé

Yaël P. Mossé is a scholar working on Neurology, Cancer Research and Oncology, having authored 96 papers that have together received 4.6k indexed citations. Recurring topics across this work include Neuroblastoma Research and Treatments (83 papers), Cancer, Hypoxia, and Metabolism (35 papers), Cancer therapeutics and mechanisms (30 papers), Lung Cancer Research Studies (20 papers), Neuroendocrine Tumor Research Advances (9 papers), Microtubule and mitosis dynamics (6 papers), Cancer Genomics and Diagnostics (6 papers) and Virus-based gene therapy research (4 papers). The work is most often cited by research in Neurology (2.7k citations), Cancer Research (1.7k citations) and Oncology (1.3k citations). Yaël P. Mossé has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include John M. Maris, Edward F. Attiyeh, Kristina A. Cole, Sharon J. Diskin, Brenda J. Weigel, Susan M. Blaney, Andrew Wood, Garrett M. Brodeur, Peter C. Adamson and Erica L. Carpenter. Their work appears in journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact